Disproportionate, differential and targeted treatment: people who use drugs' experiences of policing during the COVID-19 pandemic.

Walker S, Rathnayake K, Dietze P, Higgs P, Ward B, Hellard M, Doyle J, Stoove M, Maher L

COVID-19

Synthesising enablers and barriers to hepatocellular carcinoma surveillance-A systematic review of qualitative findings.

Moussa D, Flores JE, Doyle JS, Ryan M, Wallace J, Howell J

Cost-Effectiveness of Treating Hepatitis C in Clients on Opioid Agonist Therapy in Community Pharmacies Compared to Primary Healthcare in Australia.

Ginnane JF, Scott N, Radley A, Dillon JF, Hellard M, Doyle J

Financial incentives to increase engagement across the hepatitis C care cascade among people at risk of or diagnosed with hepatitis C: A systematic review.

Shen C, Dawe J, Traeger MW, Sacks-Davis R, Pedrana AE, Doyle JS, Hellard ME, Stoové M

Hepatitis C Injecting Drug Use

Long-term outcomes of a decentralized, nurse-led, statewide model of care for hepatitis C among people in prison in Victoria, Australia.

MacIsaac MB, Papaluca T, McDonald L, Craigie A, Edwards A, Layton C, Gibson A, Winter RJ, Iyer K, Sim A, Evans S, Kumaragama K, Howell J, Desmond P, Iser D, Scott N, Hellard M, Stoové M, Wilson D, Pedrana A, Doyle JS, Holmes JA, Thompson AJ.

Hepatitis C Injecting Drug Use Justice Health

Improving Hepatocellular Carcinoma Surveillance Outcomes in Patients with Cirrhosis after Hepatitis C Cure: A Modelling Study.

Cumming J, Scott N, Howell J, Flores JE, Pavlyshyn D, Hellard ME, Winata LS, Ryan M, Sutherland T, Thompson AJ, Doyle JS, Sacks-Davis R

Hepatitis C